Syngene International expands capabilities with new bioconjugation suite in Bengaluru

Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services

Syngene announces 3rd year of STEM scholarship for women with RICH

This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background

Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain

Hikal appoints Dr. Raghavendar Morthala as Head – CDMO R&T Pharma & Animal Health BU

Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO

She brings an overall Techno Commercial experience of 22+ Years in various Organizations

Syngene biologics facility to be operational for US, European customers from mid-year

New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day

Syngene International forms a new subsidiary

The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind

Syngene International to acquire stake in O2 Renewable Energy II

A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power